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IL-13–induced airway mucus production  
is attenuated by MAPK13 inhibition
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William T. Roswit,1 Chantel A. Miller,1 Richard F. Heier,1 Derek E. Byers,1  
Tom J. Brett,1,3,4 and Michael J. Holtzman1,3
1Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, 2Department of Pediatrics,  
3Department of Cell Biology, and 4Department of Biochemistry, Washington University School of Medicine, St. Louis, Missouri, USA.
Increased mucus production is a common cause of morbidity and mortality in inflammatory airway diseases, 
including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. However, the precise 
molecular mechanisms for pathogenic mucus production are largely undetermined. Accordingly, there are no 
specific and effective anti-mucus therapeutics. Here, we define a signaling pathway from chloride channel cal-
cium-activated 1 (CLCA1) to MAPK13 that is responsible for IL-13–driven mucus production in human airway 
epithelial cells. The same pathway was also highly activated in the lungs of humans with excess mucus produc-
tion due to COPD. We further validated the pathway by using structure-based drug design to develop a series 
of novel MAPK13 inhibitors with nanomolar potency that effectively reduced mucus production in human 
airway epithelial cells. These results uncover and validate a new pathway for regulating mucus production 
as well as a corresponding therapeutic approach to mucus overproduction in inflammatory airway diseases.
Introduction
An excess of airway mucous secretions is likely one of the most 
common maladies of humankind. The condition is an invariable 
feature of acute respiratory illnesses and a characteristic feature of 
chronic lung diseases, such as asthma and chronic obstructive pul-
monary disease (COPD). Indeed, mucus overproduction is likely 
responsible for much of the morbidity and mortality associated 
with all of these conditions. In the case of asthma, reports of mucus 
plugging and inspissation are typical of autopsies of patients with 
asthma (1). Similarly, much of the distress of patients with COPD 
may depend on disease of small airways that are overpopulated 
with mucous cells (2). Moreover, mucus production may be an 
early sign of a progressive decline in lung function in COPD (3). 
Excess mucus is likely due to increased biosynthesis and secretion 
of the secretory mucins (particularly MUC5AC and MUC5B) that 
are the major macromolecular constituents of airway mucus (4). 
At present, however, there is no specific and effective treatment for 
controlling overproduction of respiratory mucin or consequent 
airway mucus levels.
One of the chief reasons for the lack of effective therapeutics 
for excess mucus production is that the underlying cellular and 
molecular mechanism for this process is poorly understood. We 
reasoned that two basic questions must be resolved: first, what are 
the upstream extracellular events that drive a precursor epithelial 
cell to become a mucous cell, and second, what are the subsequent 
downstream signaling events that occur within the airway epi-
thelial cell to drive mucin gene expression? For upstream events, 
other groups and ours have provided evidence that initial stim-
uli, such as allergens, viruses, and cigarette smoking, will lead to 
immune cell production of IL-13 as the critical driver for mucus 
production (5–8). Other laboratories and ours also have shown 
that the subsequent downstream events for IL-13 signaling in 
mucous precursor cells likely involve upregulation and activation 
of the IL-13 receptor and associated STAT6 transcription factor 
(8, 9). However, the next step between these events and down-
stream mucin gene expression still needed to be defined. The lack 
of identifiable STAT6-binding sites in the MUC5AC mucin gene 
promoter indicates that intermediate steps are required to con-
vert the IL-13 signal to mucin gene expression (10, 11). In that 
regard, other studies of cultured human airway epithelial cells 
have suggested that activation of MEK1/2, PI3K, SPhk1, and 
MAPK14 (p38α-MAPK) are necessary for IL-13–induced mucus 
production (12, 13). However, these conclusions were typically 
based on the effects of chemical inhibitors at relatively high con-
centrations without target validation using genetic tools. More-
over, it remained uncertain whether these signaling events were 
associated with mucous cell metaplasia/hyperplasia and mucus 
overproduction in humans with lung disease.
In this context, we previously provided evidence that calci-
um-activated chloride channel (CLCA) genes may fulfill a critical 
role for the development of mucous cell metaplasia. For exam-
ple, gene transfer with vectors encoding mouse Clca3, Clca5, or 
Clca6 is sufficient for airway mucus production in mice (14, 15). 
Furthermore, both the mouse Clca and human CLCA gene pro-
moter regions contain consensus STAT6-binding sites that could 
mediate direct responsiveness to IL-13 stimulation (16). In addi-
tion, CLCA proteins undergo extracellular secretion and cleav-
age, suggesting that they might function as signaling molecules 
rather than ion channels (17, 18). In this work, we better defined 
the signal transduction basis for mucus production through the 
unexpected finding that human CLCA1 activates MAPK13 (also 
known as p38δ-MAPK), which in turn conveys a signal to stim-
ulate MUC5AC mucin gene expression. We detected the same 
signaling pathway to be active in humans with COPD, provid-
ing a rationale for further therapeutic development. We used a 
drug design strategy that takes advantage of target homology to 
shift the activity profile of inhibitors from MAPK14 (19) toward 
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increased activity against MAPK13 and found that these novel 
compounds effectively block IL-13–stimulated mucus production 
in human airway epithelial cells. The results thereby validate a 
novel therapeutic approach to hypersecretory diseases of the pul-
monary airways and perhaps other sites as well.
Results
CLCA1 controls mucin gene expression. The mouse Clca gene family 
contains at least 7 members, and studies of the predominantly 
upregulated member (mouse Clca3) provide evidence for redun-
dancy, since Clca3–/– mice still develop IL-13–dependent mucus 
production after viral infection and exhibit upregulation of a 
functional mouse Clca5 gene (14). Moreover, when we analyzed 
IL-13–stimulated mucus production in mouse airway epithelial 
cells in primary culture using more sensitive, specific, and quan-
titative real-time PCR assays than were used previously (20), we 
found induction of mouse Clca5 and newly discovered mouse 
Clca7 in addition to the predominant mouse Clca3 gene expres-
sion (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI64896DS1). These find-
ings raise the possibility that similar redundancy (and therefore 
difficulty in assigning function) might also occur in humans (16). 
However, the human CLCA gene family contains only 4 members, 
and, in contrast with the mouse system, we found that human 
CLCA1 but not CLCA2, CLCA3, or CLCA4 gene expression was 
increased in concert with IL-13 induction of mucous cell meta-
plasia in well-differentiated human airway epithelial cells, in this 
case using human tracheal and bronchial epithelial cells (hTECs) 
maintained under air-liquid interface conditions (Figure 1, A 
and B). Levels of CLCA2 and CLCA4 were increased during cell 
differentiation under air-liquid interface conditions, but neither 
was increased by IL-13 treatment. Levels of CLCA3 mRNA were 
undetectable under these conditions. Moreover, whole-genome 
microarray analysis (and corresponding quantitative PCR [qPCR] 
assays) of gene expression showed marked upregulation of CLCA1 
and MUC5AC mRNA levels relative to all other genes in IL-13–
stimulated hTECs (Supplemental Figure 2). Mucus production 
was signified by increased MUC5AC mRNA levels without sig-
nificant changes in MUC5B gene expression (Supplemental Fig-
ure 3), consistent with a previous report (21) and indicative of 
other controls or cellular sources for MUC5B expression (22, 23). 
The increases in CLCA1 and MUC5AC mRNA resulted in corre-
sponding increases in CLCA1 and MUC5AC protein levels, with 
significant detection of these proteins in cell lysate and apical cell 
supernatant (Figure 1, C and D). Confocal microscopy of IL-13–
stimulated hTECs immunostained for CLCA1 and MUC5AC 
showed colocalization in a spatial pattern of apical MUC5AC cou-
pled with subjacent CLCA1 (Figure 1, E and F, and Supplemental 
Video 1). Immunostaining was specific for CLCA1 and MUC5AC 
since there was no staining above background in the absence of 
primary antibody (Supplemental Figure 3). These findings are 
consistent with coordinated packaging of CLCA1 and MUC5AC 
within mucous granules as described previously (24, 25) and, 
based on the present findings, concerted synthesis and secretion 
of CLCA1 and MUC5AC to the apical cell surface in response to 
IL-13–stimulation as well.
To define the functional role of CLCA1 in regulating mucus 
production, we next analyzed the effect of specific siRNA-medi-
ated knockdown of CLCA1 gene expression. We found that stably 
transducing hTECs with siRNA directed against CLCA1 resulted in 
quantitative inhibition of IL-13–driven mucus production (Figure 
1, G and H). In this system, lentiviral transfection efficiency ranged 
from 50% to 60% (Supplemental Figure 3) and resulted in a similar 
quantitative decrease in MUC5AC mRNA and protein levels. The 
inhibitory effect was limited to IL-13–inducible mucus production, 
with no significant effect on basal mucus production. In addition, 
the inhibitory effect was specific to CLCA1 since siRNA-mediated 
knockdown did not significantly affect CLCA2 or CLCA4 mRNA 
levels, and CLCA3 was undetectable under these conditions (Sup-
plemental Figure 3). Together, the results indicate that CLCA1 is a 
master regulator of the IL-13 to mucin gene expression signaling 
pathway and, in contrast to the mouse system (14), appears to func-
tion without redundancy from other CLCA gene products. Thus, 
further studies were performed in the human system.
CLCA1-MAPK signaling in cultured cells. To determine the signaling 
mechanism for CLCA1-dependent induction of mucin gene expres-
sion, we next used NCI-H292 cells (derived from a lung mucoepider-
moid carcinoma) to establish a cell line with stable expression of the 
CLCA1 gene under the control of a doxycycline-inducible promoter 
system (referred to herein as NCI-H292-rtTA-CLCA1 cells) (as dia-
grammed in Figure 2A). Analysis of NCI-H292-rtTA-CLCA1 cells 
indicated that overexpression of CLCA1 was sufficient for mucin 
gene expression based on dose-dependent induction of CLCA1 and 
MUC5AC gene expression (Figure 2, B and C). As we found in pri-
mary-culture hTECs, the increases in CLCA1 and MUC5AC mRNA 
levels were accompanied by concomitant increases in CLCA1 and 
MUC5AC protein (Figure 2, D–F). The capacity of CLCA1 expres-
sion to be sufficient for mucin gene expression is consistent with 
our previous observations in mice, wherein gene transfer using a 
viral vector encoding the mouse Clca3 gene was also sufficient for 
mucin gene expression in vivo (14).
We next assessed downstream signaling from the CLCA1 gene 
product using phospho-MAPK antibody arrays to screen for any 
possible MAPK activation subsequent to doxycycline activation 
of CLCA1 expression. We observed that doxycycline treatment of 
NCI-H292-rtTA-CLCA1 cells caused time-dependent activation 
of 12 MAPKs (Figure 3A and data not shown). The largest doxy-
cycline-induced increase in MAPK phosphorylation (doxycycline 
treatment compared with no treatment) was found for MAPK14 
(Figure 3A), consistent with MAPK14 inhibitor blockade of cytok-
Figure 1
CLCA1 is necessary for IL-13–stimulated mucus production in human 
airway epithelial cells. (A) hTECs were incubated with IL-13 (50 ng/ml) 
under submerged conditions for 2 days and then air-liquid interface 
conditions for up to 21 days, and cell lysates were analyzed for CLCA1, 
CLCA2, and CLCA4 mRNA levels by real-time qPCR assay. CLCA3 
mRNA was undetectable under these conditions (data not shown). (B) 
Corresponding levels of MUC5AC mRNA. (C) Corresponding levels of 
CLCA1 in cell lysate and apical cell supernatant determined by ELISA. 
(D) Corresponding levels of MUC5AC determined by ELISA. (E) Corre-
sponding immunocytochemistry for DAPI, CLCA1, and MUC5AC using 
confocal microscopy. Scale bar: 50 μm. (F) Corresponding immunocy-
tochemistry at a more apical (high z axis) and subjacent (low z axis) 
cellular location. Arrows indicate the same reference cells for high 
and low z axis. Scale bar: 50 μm. (G) Levels of CLCA1 and MUC5AC 
mRNA in hTECs that were transduced with lentivirus encoding CLCA1 
or control shRNA. (H) For conditions in E, corresponding cellular levels 
of CLCA1 and MUC5AC by ELISA. All values represent mean ± SEM. 
*P < 0.05, increase from corresponding no IL-13 treatment control or 
decrease from no shRNA treatment.
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ine-induced MUC5AC gene expression in airway epithelial cells 
(12, 13, 21, 26). However, blockade was only achieved at relatively 
high (10–20 μM) concentrations of inhibitor that may no longer 
be specific for MAPK14 (27). Moreover, others found no effect 
of MAPK14 inhibitors on PMA-induced MUC5AC expression in 
NCI-H292 cells or airway epithelial cells (11, 28). Thus, we were 
impressed with a similarly large increase in phosphorylation of 
MAPK13, which shares some degree of susceptibility to MAPK 
inhibitors but has no certain function in this cell system or oth-
ers, especially relative to other MAPK family members. Moreover, 
baseline and doxycycline/CLCA1-dependent increases in MAPK 
activity were fully blocked with BIRB-796, which exhibits activity 
against the entire MAPK subfamily (i.e., MAPK11–MAPK14) (29). 
We therefore questioned whether MAPK13 might regulate mucin 
gene expression and whether BIRB-796 might be used as a tool 
compound for assessing this possibility.
Figure 2
CLCA1 expression is sufficient for mucus production in lung epithelial cells. (A) Diagram for constructs used to establish an NCI-H292 cell line 
carrying rtTA- and CLCA1-expression cassettes. (B) Doxycycline dose response for mucin gene expression in the NCI-H292-rtTA-CLCA1 cell 
line. Cells were treated with doxycycline (0–10 μg/ml) for 48 hours, and CLCA1 and MUC5AC mRNA levels were determined by real-time qPCR 
assay. (C) Time course for mucin gene expression in NCI-H92-rrTA-CLCA1 cells. Cells were treated with doxycycline (7.5 μg/ml) for 0 to 72 hours. 
(D) Dose response for mucus protein levels in NCI-H292-rtTA-CLCA1 cells. Cells were treated with doxycycline for 48 hours, and MUC5AC levels 
were determined by cell-based ELISA. (E) Time course for mucus protein levels in NCI-H92-rrTA-CLCA1 cells. Cells were treated with doxycycline 
(7.5 μg/ml for 0 to 72 hours), and MUC5AC levels were determined by ELISA. (F) Representative immunocytochemistry for NCI-H92-rrTA-CLCA1 
cells treated with doxycycline (7.5 μg/ml for 48 hours) and then incubated with Sytox nuclear stain and immunostained for CLCA1 and MUC5AC. 
Scale bar: 100 μm. (B–E) Values represent mean ± SEM. *P < 0.05, increase from corresponding no doxycycline treatment control.
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Figure 3
MAPK13 is necessary for CLCA1-driven mucus production in lung epithelial cells. (A) NCI-H292-rtTA-CLCA1 cells were treated with doxycycline 
(7.5 μg/ml for 18 hours) with or without BIRB-796 (10 μM), and cell lysates were analyzed by phospho-MAPK antibody array. The box indicates 
results for MAPK values. Values represent the percentage of positive control (mean ± SEM). *P < 0.05, increase from corresponding no doxycy-
cline control. (B) Cells were treated as in A at indicated concentrations of BIRB-796, SB-203580, and vehicle control, and levels of CLCA1 and 
MUC5AC mRNA were determined by real-time qPCR assay. (C) Corresponding MUC5AC levels determined by cell-based ELISA. (D) Cells were 
transfected with or without control or MAPK13 or MAPK14 siRNA, (25 nM) and treated with or without doxycycline (7.5 μg/ml for 48 hours), and 
levels of MAPK13, MAPK14, and CLCA1 mRNA were determined by real-time qPCR. (E) Corresponding levels of MUC5AC mRNA for conditions 
in D. (F) Corresponding MUC5AC levels determined by cell-based ELISA for conditions in D. (B–F) Values represent mean ± SEM. *P < 0.05, 
decrease from corresponding no drug treatment or no siRNA control.
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We subsequently found that BIRB-796 markedly inhibited 
doxycycline-induced MUC5AC mRNA and MUC5AC protein 
production, whereas SB-203580, which more selectively blocks 
MAPK14 (30), did not significantly inhibit MUC5AC synthe-
sis (Figure 3, B and C). We found no effect of MAPK inhibition 
on CLCA1 expression. We next used MAPK13 RNAi to suppress 
expression and thereby define loss of function for MAPK13 in 
the regulation of mucin gene expression. We found that suppres-
sion of MAPK13 expression did not influence doxycycline-in-
duced expression of CLCA1 but completely blocked expression of 
MUC5AC gene expression (Figure 3, D and E). By contrast, treat-
ment with MAPK14 RNAi did not block doxycycline-induced 
MUC5AC synthesis or influence CLCA1 mRNA levels (Figure 3, 
D and E). Blockade of MUC5AC mRNA induction was reflected 
Figure 4
MAPK13 is necessary for IL-13–driven mucus production in human airway epithelial cells. (A) hTECs were incubated with IL-13 for 21 days, as 
described in Figure 1, with or without BIRB-796 or SB-203580, and levels of CLCA1 and MUC5AC mRNA were determined by real-time qPCR 
assay. (B) Corresponding MUC5AC levels determined by cell-based ELISA for conditions in A. (C) hTECs were transduced with lentivirus encod-
ing MAPK13, MAPK14, or control shRNA and then were treated with IL-13 for 21 days, as described in Figure 1. Cell lysates were analyzed for 
CLCA1, MAPK13, and MAPK14 mRNA levels using real-time qPCR assay. (D) Corresponding levels of MUC5AC mRNA. (E) Corresponding 
MUC5AC levels determined by cell-based ELISA. (A–E) Values represent mean ± SEM. *P < 0.05, decrease from corresponding no drug treat-
ment or shRNA control condition.
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in inhibition of corresponding MUC5AC protein levels (Figure 
3F). These results placed MAPK13 downstream of CLCA1 and 
upstream of MUC5AC gene expression in NCI-H292 cells.
A similar influence of MAPK13 over mucin gene expression 
was found in primary-culture hTECs incubated with IL-13. Thus, 
p38-MAPK blockade with BIRB-796 markedly suppressed IL-13–
induced MUC5AC gene expression, without affecting correspond-
ing CLCA1 mRNA levels, whereas treatment with SB-203580 had no 
significant effect on CLCA1 or MUC5AC gene expression (Figure 4, 
A and B). Furthermore, suppression of MAPK13 expression (using 
2 different shRNA sequences delivered with a lentiviral vector) did 
not influence IL-13–induced expression of CLCA1 but significantly 
blocked the expected increase in MUC5AC mRNA levels (Figure 4, 
C and D). In this system, lentiviral transfection efficiencies of 50% 
Figure 5
Evidence of a CLCA1 to MAPK13 signaling pathway for IL-13–stimulated mucus production in COPD. (A) Levels of IL13, CLCA1, MAPK13, and 
MUC5AC mRNA in lung tissues from lung transplant donors without COPD (n = 4) and recipients with very severe COPD (n = 9). (B) Levels of 
CLCA1 and MUC5AC determined by ELISA from lung samples obtained as in A. Values represent mean of triplicate values for each subject. (A 
and B) For box-and-whisker plots, whiskers represent range, the plus sign indicates mean values, and boxes indicate 25th to 75th percentiles. 
*P < 0.05, difference from non-COPD control. (C) Representative photomicrographs of corresponding lung sections subjected to immunostaining 
for CLCA1 and MUC5AC. Scale bar: 100 μm. (D) Levels of MAPK activation based on analysis of phospho-MAPK antibody array for lung samples 
obtained as in A. Values represent percentage of positive control (mean ± SEM). *P < 0.05.
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to 60% again resulted in a similar quantitative decrease in MAPK13 
and MUC5AC mRNA and protein levels. Transduction of airway 
epithelial cells with lentivirus encoding MAPK14 shRNA achieved 
a similar selective decrease in target mRNA but showed no signifi-
cant effect on IL-13–induced MUC5AC gene expression (Figure 4D) 
or CLCA1 mRNA levels (Figure 4C). Blockade of MUC5AC mRNA 
induction was again reflected in significant decreases in correspond-
ing MUC5AC protein levels (Figure 4E).
CLCA1/MAPK13 signaling in human lungs. We next extended our 
studies of CLCA1/MAPK13 signaling in isolated cells to studies of 
this pathway in whole lungs with excess mucus production. Our 
approach took advantage of whole lung explants from recipients 
undergoing lung transplantation for very severe (GOLD stage 
IV) COPD compared with lungs from non-COPD donors. Lim-
ited clinical information was available for non-COPD subjects, 
but the group of patients with very severe COPD was character-
ized by severe emphysema and symptoms of chronic bronchitis 
signified by excess mucus production (Supplemental Table 1). To 
address the relationship of CLCA1 expression to airway mucus 
production, we examined lung tissue core samples directed to 
airways based on computed tomography imaging (31). In these 
airway-rich core samples, we found a significant increase in CLCA1 
and MUC5AC mRNA as well CLCA1 and MUC5AC protein levels 
in subjects with COPD compared with subjects without COPD 
(Supplemental Figure 4). Moreover, CLCA1 levels correlated with 
MUC5AC levels across the group of COPD and non-COPD lung 
samples (Supplemental Figure 4).
We next performed a more detailed analysis of the CLCA1/
MAPK13 signaling pathway in a subset of subjects and found that 
lung tissue obtained from patients with COPD exhibited signifi-
cant increases in IL13 and MUC5AC gene expression (consistent 
with our previous observations in a smaller group of subjects; refs. 
6, 8) as well as increased CLCA1 and MAPK13 gene expression (Fig-
ure 5A). The increases in CLCA1 and MUC5AC mRNA were also 
reflected in increased levels of the corresponding proteins (Fig-
ure 5B). Immunostaining of lung tissue samples demonstrated 
colocalization of CLCA1 and MUC5AC in mucosal mucous cells 
(Figure 5C). Furthermore, increases in CLCA1 and MAPK13 gene 
expression were accompanied by significant increases in MAPK13 
activation that were relatively prominent compared with those of 
other MAPKs (Figure 5D). Thus, IL-13 stimulation of a CLCA1/
MAPK13 signaling pathway to mucin genes found in human 
airway epithelial cells in culture appears to also be activated in 
human lungs in vivo during chronic obstructive lung disease.
We also investigated whether the homologous Clca/Mapk sig-
naling pathway could be found in whole lungs of mice. However, 
we recognized that the observed differences between the mouse 
Clca and human CLCA gene loci and the apparent redundancy in 
mouse Clca responsiveness to IL-13 signaling might indicate a cor-
responding difference in downstream human CLCA versus mouse 
Clca signaling as well. Nonetheless, the availability of Mapk13- 
deficient mice (32) provided a suitable genetic approach for test-
ing whether a comparable signaling system might be present in 
a potentially useful animal model. In fact, similar to that in the 
human system, we found an increase in mouse Clca3 mRNA levels 
in response to IL-13 administration in the lungs of Mapk13–/– mice 
and same-strain wild-type control mice. However, we found no dif-
ference in levels of Muc5ac mRNA in the lung or corresponding 
Muc5ac immunostaining in the airways of Mapk13–/– mice com-
pared with those of wild-type mice (Supplemental Figure 5). Simi-
larly, we found the usual increase in mouse Clca3 but no difference 
in Muc5ac mRNA response to IL-13 in primary-culture mouse tra-
cheal epithelial cells from Mapk13–/– and wild-type control mice 
(Supplemental Figure 5). Together, these findings reinforced 
the position that the mouse model was not representative of the 
human for IL-13–dependent control of airway mucus production 
and that further studies to inhibit excess mucus production might 
be best performed in humans or human subject materials.
Design and validation of MAPK13 inhibitors. Taken together, our 
results in human cells and lungs pointed to a central role for 
MAPK13 in regulating airway mucus production and there-
fore suggested the utility of a more potent MAPK13 inhibitor. 
To develop such a compound, we used a drug discovery strategy 
known as scaffold hopping that starts with a known active com-
pound and ends with a novel chemical entity by modifying the cen-
tral core structure of the molecule (33, 34). In the present case, the 
strategy was designed to take advantage of MAPK13 and MAPK14 
homology (60% sequence identity) and thereby provide new ana-
logs of MAPK14 inhibitors with improved affinity for MAPK13. We 
recognized that BIRB-796 exhibited potent inhibition of MAPK14 
(the original target for this compound) but relatively weak activ-
ity for MAPK13 (29). The selectivity of BIRB-796 for MAPK14 is 
based largely on incorporating a naphthalene group into part of 
the molecule (i.e., a naphthalene moiety) that can readily occupy 
a distinct binding site (designated the gatekeeper pocket) in 
MAPK14 but not the more confined pocket in MAPK13. The dif-
ference in access to this pocket appeared to be under the control 
of the adjacent gatekeeper residue, which is a small threonine in 
MAPK14 compared with a large methionine in MAPK13. To initi-
ate our structure-based drug design approach, we first crystallized 
and determined the structure of inactive uncomplexed MAPK13 at 
high resolution. Indeed, superposition of the MAPK14–BIRB-796 
cocrystal structure onto MAPK13 revealed interference (i.e., a steric 
clash) between the gatekeeper methionine and the inhibitor naph-
thalene moiety (Figure 6A and Supplemental Figure 6).
Figure 6
Discovery and validation of potent MAPK13 inhibitors. (A) Superpo-
sition of BIRB-796 into the MAPK13 binding pocket. The position of 
the gatekeeper Met107 is shown in a space-filling model. Circles indi-
cate ATP-binding and Phe pockets. (B) Crystal structure of compound 
61 (cyan) bound to MAPK13 in DFG-out mode. Difference electron 
density for the compound following rigid-body refinement is shown in 
mesh. Circles indicate binding pocket features. Phe169 (of the DFG 
sequence) is highlighted in yellow. (C) Crystal structure of compound 
124 (magenta) bound to MAPK13 in DFG-in mode. (D) MAPK13 bind-
ing pockets for compound 61 (cyan) and compound 124 (magenta). 
All residues that make van der Waals contacts or polar contacts are 
shown. Residues that make direct hydrogen bonds (black lines) with 
inhibitors are labeled in black. (E) BioLayer interferometry sensorgrams 
for compound 61 and 124 binding to MAPK13. Processed data are 
shown as black lines with global kinetic fits overlaid as red lines. (F) 
MAPK13 inhibitory activity in a screen of test compounds (numbered 
from 43–205 and arranged from most to least potent) using IMAP 
assay. Values represent IC50 for compounds with values <20 μM. Red-
colored bars indicate compounds selected for detailed analysis. (G) 
Concentration response for MAPK13 inhibition for indicated test com-
pounds. Values represent fluorescence polarization (mP) from IMAP 
assay. (H) hTECs were cultured with or without IL-13 for 21 days with 
the indicated compounds, and MUC5AC levels were determined by 
ELISA. (G and H) Values represent mean ± SEM. *P < 0.05, decrease 
from no drug treatment condition.
Downloaded on October 19, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/64896
research article
4564 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 12   December 2012
We therefore used BIRB-796 as a starting compound to build 
slimmer analogs that would no longer clash with the gatekeeper 
residue and maintain other beneficial structural features to thereby 
exhibit greater potency for MAPK13. We were particularly inter-
ested in BIRB-796 because it binds to MAPK14 in the Asp-Phe-Gly–
out mode (DFG-out mode) (35). This binding mechanism results 
in rotation of the conserved DFG motif out of the Phe-binding 
pocket (i.e., DFG-out) and thereby produces a prolonged dissoci-
ation rate that might offer a pharmacological advantage (35–37). 
With the aid of protein structure modeling, we designed and syn-
thesized analogs that incorporated a smaller monoaryl ring in place 
of the bulky naphthalene in BIRB-796 to prevent clashing with 
the gatekeeper methionine (Supplemental Figure 7). Analysis of 
analog-MAPK13 cocrystals confirmed successful binding that pre-
served contacts and hydrogen bonds with the same MAPK13 resi-
dues (Figure 6, B and C; Supplemental Figure 8; and Supplemental 
Table 2). However, while some analogs (e.g., compound 61) demon-
strated the expected DFG-out binding mode, other analogs (e.g., 
compound 124) adopted DFG-in binding due to conformational 
constraints imposed by the fit to the binding pocket. In concert 
with these results, analogs with DFG-out binding (e.g., compound 
61) maintained slow dissociation kinetics, while those exhibiting 
DFG-in binding (e.g., compound 124) formed short-lived com-
plexes (Figure 6, D and E). We anticipated that these structural and 
kinetic differences might translate into differences in compound 
potencies in enzyme and cellular assays of MAPK13 activity.
All analogs were tested for inhibition of MAPK13 enzyme activ-
ity using an immobilized metal affinity polarization (IMAP) assay 
that detected fluorescence polarization as a function of remaining 
MAPK13 activity. As expected, DFG-out binding compounds (e.g., 
compound 61 and, a similar compound, compound 62) displayed 
highly potent MAPK13 inhibition, whereas DFG-in binding com-
pounds (e.g., compound 124) with otherwise similar structure 
displayed 65-fold to 120-fold lower inhibitory activity (Figure 
6F). Structurally distinct AMG-548 and SB-203580 also exhibited 
weak inhibitory activity consistent with lower affinity for MAPK13 
compared with MAPK14 (30, 38). More detailed 16-point inhibitor 
concentration-response curves were performed for representative 
compounds (Figure 6G). This analysis further confirmed that, 
within our chemical series, the most active DFG-out compounds 
(i.e., compounds 61 and 62) were more potent than a representa-
tive DFG-in compound (i.e., compound 124) and compared favor-
ably with less selective inhibitors designed to inhibit MAPK14, i.e., 
AMG-548 and SB-203580 (Figure 6G and Supplemental Table 3). 
As expected, all of these compounds continued to show inhibitory 
activity against MAPK14 as well (Supplemental Table 4 and Sup-
plemental Figure 9), since the compounds should continue to fit 
into the MAPK14 gatekeeper pocket and no changes were made to 
interfere with binding at other sites in the MAPK molecules.
Nonetheless, the greater potency of newly designed compounds 
for blocking MAPK13 suggested that these compounds would have 
greater potency for blocking IL-13–dependent mucus production. 
Accordingly, we next tested the effect of representative analogs on 
mucus production in comparison to the effects of compounds 
designed to inhibit MAPK14. We found that potency for MAPK13 
inhibition correlated closely with blockade of mucus production. 
Thus, the most potent MAPK13 inhibitors (compounds 61 and 
62) suppressed IL-13–induced MUC5AC production in primary-
culture human airway epithelial cells with 50% inhibition at 10–8 
M, whereas treatment with less potent MAPK13 inhibitors (com-
pound 124 and AMG-548) had no significant effect on MUC5AC 
level until treatment with 10–6 M (Figure 6H). None of the tested 
compounds resulted in significant changes in transepithelial elec-
trical resistance, even at 10–6 M, indicating a lack of cytotoxic effect 
despite treatment for 21 days (Supplemental Figure 10). Taken 
together, the findings reveal a potent and effective action of ratio-
nally designed MAPK13 inhibitors in blocking IL-13–induced 
mucus production in primary-culture human airway epithelial cells 
under culture conditions that maintain the features of a well-differ-
entiated airway mucosa found in vivo.
Discussion
In this report, we establish the critical role of CLCA1 and MAPK13 
in controlling excess mucus production that is typical of inflam-
matory airway disease. We use genetic and chemical tools to define 
a signaling pathway that begins with IL-13 induction of CLCA1 
gene expression and proceeds to CLCA1-mediated activation of 
MAPK13 and consequent MUC5AC mucin gene expression (Fig-
ure 7). Pathway function was established by gain and loss of func-
tion for CLCA1 and MAPK13 in primary-culture human airway 
epithelial cells and representative cell lines and in lung explants 
from patients with excess mucus due to COPD. This approach to 
Figure 7
Scheme for CLCA1/MAPK13 signaling to mucus production. 
The CLCA1/MAPK13 signaling pathway is initiated when 
environmental stimuli (e.g., allergen or virus) stimulate IL-13 
production and subsequent activation of IL-13 receptor on 
the surface of mucous precursor cells. IL-13 receptor activa-
tion leads to STAT6 activation and consequent induction of 
CLCA1 gene expression. The CLCA1 protein is secreted as 
N-terminal and C-terminal CLCA1 (N-CLCA1 and C-CLCA1) 
peptide fragments that might activate a putative CLCA1 
receptor and in turn MAPK13 to drive a consequent increase 
in mucin (especially MUC5AC) gene expression and mucus 
production in airway mucous cells.
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acknowledged to transmit extracellular signals to intracellular 
targets via upstream receptors (46, 47). The nature of a putative 
CLCA1 receptor that might be linked to MAPK13 activation is 
currently under study. Similarly, at least some CaCCs may also 
trigger MAPK signaling (e.g., TMEM16A stimulates ERK1/2 acti-
vation) (48), but the CaCC signaling pathway to activate chloride 
transport still needs to be defined. Nonetheless, the combination 
of previous and present work serves to position CLCA1 as a central 
signaling protein for controlling both the glycoprotein and fluid 
components of mucus production.
In regard to CLCA1 control of mucus production, a third reason 
for the present advance was the need for an unbiased approach 
to CLCA1 signaling targets and the particular advantage of anti-
body arrays to screen for these targets to find MAPK13. The rela-
tively unstudied MAPK13 was originally described as responsive 
to inflammatory cytokines and cellular stress but downstream 
targets were uncertain (49). Subsequent reports suggested a role 
for MAPK13 in keratinocyte differentiation and survival (50, 51), 
microtubule assembly and neurogeneration (52), attenuation of 
insulin secretion (53), and cell proliferation in skin cancer and 
cholangiocarcinoma (54, 55); however, no complete scheme has 
emerged for MAPK13 activity in human disease. Instead, most 
previous work has concentrated on other MAPK family members, 
primarily MAPK14, as contributing to inflammation in the air-
way and other sites (56) as well as driving mucus production (12, 
26). Based on these observations, drug development activity was 
generally directed at MAPK14, yielding inhibitors with increased 
kinase selectivity and antiinflammatory activity (19, 57). The pres-
ent results assign a new function for MAPK13 and should turn 
the field to a different strategy for the study of MAPK biology and 
blockade. Though here again we caution an approach that uses the 
mouse model, in which MAPK13 has recently been shown to regu-
late other types of kinase-dependent responses (e.g., TLR4-driven 
ERK1/2 activation in immune cells) (58).
Finally, a key reason for the lack of previous progress on 
MAPK13 function was the absence of potent chemical inhibitors 
of MAPK13. Indeed, this project benefited greatly from the iden-
tification of more potent MAPK13 inhibitors. We developed these 
inhibitors guided by structural analysis of MAPK13-inhibitor coc-
rystals and scaffold hopping from compounds that were designed 
previously to bind selectively to the homologous MAPK14. Our 
approach allowed for the discovery of potent MAPK13 inhibitors 
that better fit the MAPK13 gatekeeper pocket and maintained 
a DFG-out mode with slow dissociation kinetics (35, 36). Com-
pounds that achieved these end points (e.g., compounds 61 and 
62) provided for an approximate 100-fold increase in MAPK13-in-
hibitor complex half-life and a 100-fold increase in mucus inhibi-
tion. These properties should translate into more sustained and 
potent effects for use as tool compounds and for further drug 
development. It is also possible that the combination of gate-
keeper- and Phe-pocket binding will improve kinase selectivity. 
However, the present inhibitors maintain their activity against 
MAPK14. Thus, the chemical approach to MAPK13 inhibition 
was scientifically complemented and validated by the concomi-
tant genetic approach, and additional work will have to be done 
to fully characterize the kinase specificity of the present com-
pounds and perhaps to develop others with greater specificity. 
Recent success in developing extremely selective MAPK14 inhib-
itors (59, 60) suggests that this is an achievable step. Although 
compounds with combined MAPK13 and MAPK14 activity may 
incorporate human subjects and materials was essential due to the 
substantial differences in CLCA protein families between humans 
and other species (including mice) (14, 16) and the consequence 
divergence in downstream CLCA signaling as well.
Indeed, the first reason for the present advance in understand-
ing CLCA1 function was the shift from mouse to human model 
systems. Thus, the initial discovery of the role of CLCA proteins in 
airway disease was derived from studies of inbred and intercrossed 
mice in which whole-genome assessment revealed linkage between 
mouse Clca3 gene expression and mucus production after respi-
ratory viral infection (14). However, this model also showed that 
loss of Clca3 function (using newly developed Clca3–/– mice) did not 
influence IL-13–driven mucus production and led to the initial 
concern that Clca proteins were not involved in regulating excess 
mucus production during inflammatory airway disease. However, 
further genetic analysis also revealed that the mouse Clca gene fam-
ily contained at least 7 members, so that gene duplication and func-
tional redundancy could account for preservation of the postviral 
mucus phenotype if only a single Clca gene was inactivated. In fact, 
additional analysis of this mouse model showed that other Clca 
family members were also sufficient for driving mucus production 
(14, 15). Similarly, in this study, we found IL-13 upregulation of 
mouse Clca5 and Clca7 as well as predominant Clca3 gene expres-
sion in mouse airway epithelial cells. In addition, we found that 
the connection between CLCA expression and MAPK13 activation 
present in humans was not apparent in mice. Thus, IL-13 induc-
tion of Muc5ac gene expression was not blocked by Mapk13 defi-
ciency (using Mapk13–/– mice compared with wild-type control 
mice) either in vivo (using mice treated with inhaled IL-13) or in 
vitro (using primary-culture mouse tracheal epithelial cells treated 
with IL-13). It was therefore critical to assess the epithelial mucus 
system in humans to establish selective induction of CLCA1 and 
activation of MAPK13 as key events for regulating IL-13–inducible 
mucus production and secretion in isolated cells and whole lungs.
A second reason for the current progress on CLCA1 function 
relates to the role of CLCA1 as a signaling molecule compared 
with the original assignment (based on sequence homology) as an 
integral membrane protein that functioned as a calcium-activated 
chloride channel (CaCC). In that regard, even the initial bioinfor-
matic (16) and experimental data (17, 18, 39) indicated that CLCA 
proteins generally lack the structural features to form ion channels 
by themselves, since they either contain only a single transmem-
brane anchor or exhibit secretion from the cell in soluble form. 
Moreover, subsequent findings were more consistent with the 
proposal that CLCA1 effects on chloride transport may be based 
on increasing conductance of endogenous CaCCs (40). It further 
appears (based on analysis of crude membrane preparations) that 
secreted CLCA proteins are first processed intracellularly into 
N-terminal and C-terminal peptide fragments (18, 39, 41–44). The 
present findings support this alternative proposal as well, in that 
CLCA1 is colocalized within the cell along with MUC5AC in secre-
tory granules and is secreted to the apical cell surface in response 
to IL-13. Our initial structural work with purified human CLCA1 
protein suggests that a novel form of self-cleavage is required for 
secretion and that the consequent production of the N-terminal 
fragment of CLCA1 is sufficient for stimulating CaCC activity 
(45). The present connection between CLCA1 and MAPK13 acti-
vation and downstream mucin gene expression further support 
the proposal that CLCA1 functions as a signaling molecule, since 
MAPKs in general and p38-MAPKs in particular have always been 
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of MUC5AC was obtained from G.C. Hansson (Goteburg University, 
Gothenburg, Sweden), and the epitope was expressed in 293F cells and 
purified as described previously (65). Protein cell and tissue lysates were 
plated on Nunc Maxisorp ELISA Plates (Thermo Nalge Nunc) in carbon-
ate-bicarbonate buffer and incubated at 37°C overnight. The plates were 
then washed with PBS-0.05% Tween-20 (Sigma-Aldrich) and blocked 
overnight with Sea Block blocking buffer (Thermo Pierce Biotechnol-
ogy). The reaction was developed using the 45M1 biotin-conjugated mAb 
antibody and avidin-HRP using the 1-Step UltraTMB-Elisa substrate 
(Thermo Pierce Biotechnology) and assessed for absorbance relative to 
standard 45M1 concentration.
CLCA1 ELISA. For determinations of CLCA1 in cell lysates, the CLCA1 
ELISA was based on rabbit anti-CLCA1 polyclonal antibody raised against 
N-terminal amino acids 681–693 for detection and purified recombinant 
CLCA1-3xFLAG containing these residues as standard. For determinations 
of CLCA1 in cell lysate versus supernatant and in lung tissue samples, the 
CLCA1 ELISA was based on anti-CLCA1 mAb (clone 8D3) raised against 
N-terminal CLCA1 amino acids 22–694 and purified N-terminal CLCA1 
as standard.
CLCA1-expressing cell lines. To generate lung cell lines that stably expressed 
CLCA1 driven by the tetracycline-inducible gene promoter system, human 
lung mucoepidermoid carcinoma NCI-H292 cells were transfected with 
pCMV-rtTA (rTetR-VP16) (Clonetech), and clones were selected with G418 
(200 μg/ml). Clones with low background and high induction of luciferase 
gene expression when transfected with pTRE-Tight-luciferase (Clonetech) 
and treated with doxycycline (10 μg/ml) were selected for a second transfec-
tion with a TRE-driven CLCA1-expressing plasmid. Cell lines (NCI-H292-
rtTA-CLCA1 lines) with stable expression of pCMV-rtTA and pTRE-CMV-
CLCA1 were selected with G418 and hygromycin (20 μg/ml). The CLCA1 
gene was cloned from hTEC RNA and was inserted into pTRE-Tight using 
5′-NotI and 3′-EcorV restriction enzyme sites. All constructs were verified 
by DNA sequencing.
MAPK phospho-arrays. MAPK activation was assessed using a human 
phospho-MAPK antibody array (Proteome Profiler MAPK Array, R&D 
Systems) according to the manufacturer’s instructions. The chemilu-
minescent signal from the arrays was captured on film, digitized with a 
PowerLook 1120 scanner (UMAX) using SilverFast Ai software (LaserSoft 
Imaging), and quantified with ArrayVision 8.0 software (GE Healthcare 
Life Sciences).
Gene knockdown with siRNA. MAPK13 or MAPK14 Stealth RNAi (Life 
Technologies) was transfected into NCI-H292-rtTA-CLCA1 cells using 
Lipofectamine RNAiMax (Life Technologies). Cells were then incubated in 
the RNAi-Lipofectamine mixture for 24 hours at 37°C and then with doxy-
cycline for an additional 24 hours. Cellular RNA was isolated and reversed 
transcribed using the High-Capacity cDNA Archive Kit (Life Technolo-
gies), and target mRNA levels were determined by qPCR assay.
Human lung samples. Human tissue was obtained from lung explants har-
vested at the time of lung transplantation from recipients (n = 20) with very 
severe COPD (GOLD stage IV) during the period from 2005–2009 at Barnes- 
Jewish Hospital. Control samples were obtained from donors without 
COPD (n = 11) using both lung explants that were otherwise not useable 
for transplantation and excess lung tissue that was resected for downsiz-
ing. For airway-specific analyses of gene and protein expression, computed 
tomography imaging and gross histologic examination was used to select 
airway-containing tissue cores in COPD explants (n = 11) and frozen lung 
tissues from donors without COPD (n = 7) as described previously (31). 
Each analysis consisted of samples from recipients with COPD with the 
same clinical characteristics (as summarized in Supplemental Table 1). All 
human studies were conducted with protocols approved by the Washing-
ton University School of Medicine Institutional Review Board.
offer a clinical advantage for diseases such as COPD that manifest 
both mucus and inflammatory components in the disease pro-
cess. Indeed, there is ongoing clinical development of MAPK14 
inhibitors to block inflammation in COPD and asthma (61, 62). 
In either case, the present identification and validation of the 
CLCA1 to MAPK13 signaling pathway to excess mucus produc-
tion offers an opportunity to better define the regulation of a 
major disease end point and to respond to the unmet need for an 
anti-mucus therapeutic for inflammatory airway disease.
Methods
See the Supplemental Methods for more details.
Primary culture of human airway epithelial cells. hTECs were isolated by 
enzymatic digestion, seeded onto permeable filter supports, and grown as 
described previously (6). For the present experiments, cells were cultured 
in DMEM-Ham’s F12 medium with 2% NuSerum (BD), Primocin (100 μg/
ml, InvivoGen), and retinoic acid (1 × 10–8 M, Sigma-Aldrich) with or with-
out IL-13 (50 ng/ml, Peprotech) under submerged conditions for 2 days 
and then air-liquid interface conditions for 3 weeks. Cells were also cul-
tured in the presence or absence of inhibitors that were added 1 day before 
addition of IL-13 and were readded with each IL-13 treatment (twice per 
week). Transepithelial electrical resistance of cell cultures was monitored 
as described previously (63).
Real-time qPCR assay. Target mRNA levels were quantified with real-time 
qPCR using fluorogenic probe/primer combinations specific for CLCA1, 
CLCA2, CLCA4, MUC5AC, MAPK13, MAPK14, and GAPDH (Supplemental 
Table 5). All PCR assays were quantitative and used plasmids containing 
the target gene sequences as standards. All probes were designed to span an 
intron and did not react with genomic DNA. All real-time PCR data were 
normalized to the level of GAPDH (1 × 107 copies) to correct for variation 
between samples as described previously (8).
Immunostaining. Cells were fixed, permeabilized, treated for epitope 
retrieval, and then were incubated with mouse anti-MUC5AC biotin-conju-
gated mAb and rabbit anti-CLCA1 antibody followed by Alexa Fluor 488– 
or 555–conjugated streptavidin or Alexa Fluor 555– or 633–conjugated 
goat anti-rabbit secondary antibody, counterstained with DAPI or Sytox 
Green and then imaged by confocal or conventional microscopy. Lung 
sections were incubated with citrate-based Antigen Unmasking Solution 
(Vector Laboratories) for antigen retrieval and then with anti-MUC5AC 
mAb and anti-CLCA1 antibody, followed by Alexa Fluor 488–conjugated 
streptavidin and Alexa Fluor 555–conjugated goat anti-rabbit IgG.
Generation of shRNA-expressing cells. Lentiviral vectors expressing 
siRNA from shRNA were obtained from the MISSION shRNA library 
(Sigma-Aldrich). A set of shRNA clones (constructed within the lentivi-
rus plasmid pLKO.1-Puro) was obtained for each of the following mRNA 
targets: CLCA1 (NM_001285), MAPK13 (NM_002754), and MAPK14 
(NM_001315). Lentiviral particles for each of the clones were generated 
by transfecting HEK 293T cells with shRNAi-pLKO.1-Puro plasmid, 
pHR’8.2deltaR packaging plasmid, and pCMV-VSV-G envelope plasmid 
using Fugene6 (Roche Applied Science) as the transfection agent (64). The 
shRNA lentiviral particles were added to the apical and basal sides of hTEC 
cultures for 24 hours at MOI 1, and 10 days later, cells were treated with or 
without IL13 as described above.
MUC5AC ELISA. For cell-based MUC5AC ELISA, cells were fixed 
and incubated with blocking buffer followed by mouse anti-MUC5AC 
mAb and then NeutrAvidin-HRP (Thermo Pierce Biotechnology) for 
absorbance at 450 nm. Cell number was determined with 0.5% crystal 
violet staining and absorbance at 595 nm. Values for MUC5AC levels 
were expressed as ratio of absorbance at 450 nm to 595 nm. For stan-
dard-based MUC5AC ELISA, the plasmid encoding the 45M1 epitope 
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capture biotinylated MAPK13 onto the surface of the sensor. After reach-
ing baseline, sensors were moved to association step for 300 seconds and 
then dissociated for 300 seconds. Curves were corrected by a double-ref-
erencing technique, using both biotin-coated pins dipped into the experi-
mental wells and a buffer-only reference. MAPK13-inhibitor complex half-
lives were calculated from dissociation constants determined from global 
kinetic analysis.
Statistics. Values for gene expression were analyzed using a 1-way or 2-way 
ANOVA for a factorial experimental design. PCR data were compared by 
unpaired Student’s t test with Welch’s correction for unequal variances 
when appropriate. Inhibitor effects were analyzed using 2-way ANOVA. 
P values of less than 0.05 were considered significant.
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MAPK inhibitor assay. The MAPK13 blocking activity of test compounds 
was determined using an IMAP assay containing activated MAPK13, 
FITC-labeled substrate, and test compound. IMAP assays were performed 
using the linear phase of the rate kinetics. Assay reactions contained 0–100 
μM test compound, 5–35 nM (EC80) activated MAPK13, 3 μM (Km,app) ATP, 
and 100 nM FITC-labeled EGFR peptide substrate (FITC-KRELVERLTPS-
GEAPNQALLR-NH2). The IC50 values for each compound were determined 
from the compound concentration versus fluorescence polarization (mP) 
plot using nonlinear curve fitting.
MAPK crystallization and structure determination. Human MAPK13 (amino 
acids 1–352) was expressed and purified for crystallization as described in 
the Supplemental Methods. Crystals were obtained by mixing protein solu-
tion (at 10 mg/ml) with reservoir solution (50 mM ammonium tartrate, 
18% PEG 3350) in a 4:1 (protein/reservoir) ratio. These crystals were used to 
obtain complex structures with compounds by soaking. Briefly, compounds 
dissolved in DMSO at a concentration of 100 mM were added to crystalli-
zation drops at one-tenth volume for a final concentration of 10 mM com-
pound in the drop and allowed to soak for 2 to 4 hours. X-ray diffraction 
data were collected at Advanced Photon Source beamline 19ID (nonphos-
phorylated) and Advanced Light Source (ALS) beamline 4.2.2 (compounds 
61 and 124). Data were processed using HKL-2000 software (66). The phase 
problem was solved by molecular replacement using Phaser crystallographic 
software (67). For nonphosphorylated MAPK13, the probe structure was a 
deposited structure of MAPK13 from a structural genomics project (PDB 
code: 3COI). Although our structure displayed similar crystal packing to the 
previously deposited one, there were noticeable large differences in the C-ter-
minal region revealed in our high-resolution structure (Supplemental Figure 
6). The structures of MAPK13 with compounds were isomorphous to the 
nonphosphorylated structure, so they were determined by rigid body refine-
ment. Compounds were clearly visible in Fo – Fc difference maps following 
rigid body refinement (Supplemental Figure 8). Compounds were fit to elec-
tron density maps manually using Coot software (68), and refinement was 
carried out in PHENIX software (69). Ramachandran analysis was as follows 
(% favored/% percent outliers): nonphosphorylated, 95.6/0.6; compound 61, 
96.1/0.3; and compound 124, 95.5/0.9. Final coordinates and experimental 
structure factors were deposited in the RCSB Protein Data Bank with the 
following codes: 4EXU, 4EYJ, and 4EYM. Data collection and refinement 
statistics are provided in Supplemental Table 2. All molecular graphics fig-
ures were produced using PyMOL software.
MAPK13 small molecule kinetic assay. Kinetics of MAPK13 binding to small 
molecules was assessed using BioLayer interferometry with an Octet (For-
teBio). Super-streptavidin-coated biosensors from ForteBio were used to 
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